drugset / Trial / NCT00969696
Galantamine Effects on Cognitive Function in Marijuana Users
Phase 1
Completed
29 enrolled
Yale University
National Institute on Drug Abuse (NIDA) · collabUS Department of Veterans Affairs · collab
Non-randomizedParallel-groupDouble-blindScreening
Summary
To evaluate galantamine's effects on cognitive performance in marijuana users. Galantamine, an acetylcholine esterase inhibitor, is approved for treatment of Alzheimer's disease. Current marijuana users show impaired cognitive functioning, which predicts poor treatment response to behavioral treatments in this population. Whether cognitive impairment in marijuana users will improve with medication treatment has not been evaluated. We hypothesize that galantamine, compared to placebo, will improve cognitive performance in marijuana users.Galantamine, compared to placebo, will improve working memory, verbal learning/memory and response inhibition functions in marijuana users.
Timeline
- Start
- 2009-08
- Primary completion
- 2011-06
- Completion
- 2011-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Galantamine | Small molecule | 8 mg | — |
Indications
No indication recorded.